Wang; Xi-Tao
Patent Applications and Registrations
Patent applications and USPTO patent grants for Wang; Xi-Tao.The latest application filed is for "anti-ido antibody and uses thereof".
Company Profile
23.19.23
- Wang; Xi-Tao - Wellesley MA
Patent Activity
| Patent | Date |
|---|---|
| Anti-GITR antibodies for cancer diagnostics Grant 11,408,889 - Wang , et al. August 9, 2 | 2022-08-09 |
| Anti-ido Antibody And Uses Thereof App 20210403602 - CHUNTHARAPAI; Anan ; et al. | 2021-12-30 |
| Anti-gitr Antibodies For Cancer Diagnostics App 20210011022 - WANG; Xi-Tao ; et al. | 2021-01-14 |
| Antibodies Against Ox-40 And Uses Thereof App 20200399385 - CAI; Zhehong ; et al. | 2020-12-24 |
| Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20200308282 - COGSWELL; John P. ; et al. | 2020-10-01 |
| Anti-GITR antibodies for cancer diagnostics Grant 10,690,674 - Wang , et al. | 2020-06-23 |
| Antibodies against OX40 and uses thereof Grant 10,683,357 - Cai , et al. | 2020-06-16 |
| Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,604,575 - Cogswell , et al. | 2020-03-31 |
| Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,584,170 - Cogswell , et al. | 2020-03-10 |
| Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,577,423 - Cogswell , et al. | 2020-03-03 |
| Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,323,092 - Cogswell , et al. | 2019-06-18 |
| Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,323,093 - Cogswell , et al. | 2019-06-18 |
| Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,316,091 - Cogswell , et al. | 2019-06-11 |
| Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,316,090 - Cogswell , et al. | 2019-06-11 |
| Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,308,714 - Cogswell , et al. | 2019-06-04 |
| Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20190153099 - COGSWELL; John P. ; et al. | 2019-05-23 |
| Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20190135920 - Cogswell; John P. ; et al. | 2019-05-09 |
| Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,266,594 - Cogswell , et al. | 2019-04-23 |
| Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,266,596 - Cogswell , et al. | 2019-04-23 |
| Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,266,595 - Cogswell , et al. | 2019-04-23 |
| Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20190112376 - COGSWELL; John P. ; et al. | 2019-04-18 |
| Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20190112377 - COGSWELL; John P. ; et al. | 2019-04-18 |
| Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20190100590 - Cogswell; John P. ; et al. | 2019-04-04 |
| Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20190100589 - Cogswell; John P. ; et al. | 2019-04-04 |
| Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20190092863 - Cogswell; John P. ; et al. | 2019-03-28 |
| Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,138,299 - Cogswell , et al. Nov | 2018-11-27 |
| Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20180319887 - Cogswell; John P. ; et al. | 2018-11-08 |
| Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20180312590 - COGSWELL; John P. ; et al. | 2018-11-01 |
| Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20180282414 - COGSWELL; John P. ; et al. | 2018-10-04 |
| Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20180282413 - COGSWELL; John P. ; et al. | 2018-10-04 |
| Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20180273624 - COGSWELL; John P. ; et al. | 2018-09-27 |
| Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,072,082 - Cogswell , et al. September 11, 2 | 2018-09-11 |
| Antibodies Against Ox40 And Uses Thereof App 20180237534 - CAI; Zhehong ; et al. | 2018-08-23 |
| Anti-gitr Antibodies For Cancer Diagnostics App 20180164321 - WANG; Xi-Tao ; et al. | 2018-06-14 |
| Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 9,856,320 - Cogswell , et al. January 2, 2 | 2018-01-02 |
| Antibodies Against Ox40 And Uses Thereof App 20170306035 - CAI; Zhehong ; et al. | 2017-10-26 |
| Antibodies against OX40 and uses thereof Grant 9,644,032 - Cai , et al. May 9, 2 | 2017-05-09 |
| Antibodies Against Ox40 And Uses Thereof App 20160347849 - CAI; Zhehong ; et al. | 2016-12-01 |
| Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20160090417 - COGSWELL; JOHN P. ; et al. | 2016-03-31 |
| Antibodies that bind PD-L1 and uses thereof Grant 9,212,224 - Cogswell , et al. December 15, 2 | 2015-12-15 |
| Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20150125463 - Cogswell; John P. ; et al. | 2015-05-07 |
| Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20130309250 - Cogswell; John ; et al. | 2013-11-21 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 